Is JB Chemicals and Pharmaceuticals (JBCHEPHARM) overvalued or fairly valued?

MarketChacha shows JB Chemicals and Pharmaceuticals's valuation in context — a forward P/E of about 32.8, a price-to-book of about 9.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is JB Chemicals and Pharmaceuticals's revenue?

JB Chemicals and Pharmaceuticals reported revenue of ₹3,890 Cr for FY2026, with net profit of ₹674 Cr, per official filings.

What is the share price of JB Chemicals and Pharmaceuticals (JBCHEPHARM)?

JB Chemicals and Pharmaceuticals last traded at ₹2,416.10, as of 7/16/2026 — a delayed quote shown for education, not investment advice.

JB Chemicals and Pharmaceuticals

JBCHEPHARM · NSE · Pharma · India

Snapshot

TickerJBCHEPHARM

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees5,602

HeadquartersMumbai, India

Websitewww.jbpharma.com

Filings tracked0

About JB Chemicals and Pharmaceuticals

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Who owns it

Promoters49.2%
Institutions30.8%
Public & other20.0%

87 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend13.0% → 17.1%

Margin has expanded by about 4.1 points — the business is getting more profitable.

Growth qualityrev 7% · PAT 15%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹5,441 Cr · EPS 73.70

Est. earnings growth +26.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Revenue (FY2026)

₹4,148 Cr

Net margin

17.1%

Revenue CAGR (3y)

+9.6%

Profit CAGR (3y)

+20.1%

Net profit (FY2026)

₹709 Cr

Ask MarketChacha about JBCHEPHARM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹4,148 Cr	₹709 Cr	17.1%
FY2025	₹3,918 Cr	₹660 Cr	16.8%
FY2024	₹3,484 Cr	₹553 Cr	15.9%
FY2023	₹3,149 Cr	₹410 Cr	13.0%

Quarterly

Period	Revenue	Net profit	Net margin
Q4 FY26	₹904 Cr	₹101 Cr	11.2%
Q3 FY26	₹1,065 Cr	₹198 Cr	18.6%
Q2 FY26	₹1,085 Cr	₹208 Cr	19.2%
Q1 FY26	₹1,094 Cr	₹202 Cr	18.5%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.